open access

Vol 75, No 7 (2017)
Original articles
Published online: 2017-03-31
Submitted: 2016-10-23
Accepted: 2017-03-02
Get Citation

The prognostic value of the platelet-to-lymphocyte ratio in acute coronary syndrome: a systematic review and meta-analysis

Hui Li, Yun Zhou, Yan Ma, Suxia Han, Liansuo Zhou
DOI: 10.5603/KP.a2017.0068
·
Kardiol Pol 2017;75(7):666-673.

open access

Vol 75, No 7 (2017)
Original articles
Published online: 2017-03-31
Submitted: 2016-10-23
Accepted: 2017-03-02

Abstract

Background and aim: The aim of this study was to investigate whether the platelet-to-lymphocyte ratio (PLR) is an independent predictor of all-cause mortality and cardiovascular (CV) events in patients with acute coronary syndrome (ACS).

Methods: PubMed, Embase, and the Cochrane Library were searched for relevant cohort studies regarding the association between PLR and outcomes of patients with ACS. Either a random- or a fixed-effect model was used for pooling data.

Results: Eight studies involving 6627 patients with ACS were included. The cut-off PLR value for defining risk groups was 150, and patients were assigned to the low (≤ 150) or high (> 150) PLR groups. The pooled relative risk (RR) values of in-hospital and long-term mortality were 2.15 (95% CI [confidence interval] 1.73–2.67; p < 0.00001) and 2.27 (95% CI 1.35–3.80; p = 0.002), respectively, comparing the high and the low PLR groups. Compared with the low PLR group, the high PLR group had a significantly increased risk of in-hospital (RR 1.95; 95% CI 1.30–2.91; p = 0.001) and long-term (RR 1.50; 95% CI 1.08–2.09; p = 0.01) major adverse CV events.

Conclusions: Elevated PLR was found to be a predictor of all-cause mortality and CV events.

Abstract

Background and aim: The aim of this study was to investigate whether the platelet-to-lymphocyte ratio (PLR) is an independent predictor of all-cause mortality and cardiovascular (CV) events in patients with acute coronary syndrome (ACS).

Methods: PubMed, Embase, and the Cochrane Library were searched for relevant cohort studies regarding the association between PLR and outcomes of patients with ACS. Either a random- or a fixed-effect model was used for pooling data.

Results: Eight studies involving 6627 patients with ACS were included. The cut-off PLR value for defining risk groups was 150, and patients were assigned to the low (≤ 150) or high (> 150) PLR groups. The pooled relative risk (RR) values of in-hospital and long-term mortality were 2.15 (95% CI [confidence interval] 1.73–2.67; p < 0.00001) and 2.27 (95% CI 1.35–3.80; p = 0.002), respectively, comparing the high and the low PLR groups. Compared with the low PLR group, the high PLR group had a significantly increased risk of in-hospital (RR 1.95; 95% CI 1.30–2.91; p = 0.001) and long-term (RR 1.50; 95% CI 1.08–2.09; p = 0.01) major adverse CV events.

Conclusions: Elevated PLR was found to be a predictor of all-cause mortality and CV events.

Get Citation

Keywords

platelet-to-lymphocyte ratio, acute coronary syndrome, all-cause mortality, major adverse cardiovascular events, meta-analysis

About this article
Title

The prognostic value of the platelet-to-lymphocyte ratio in acute coronary syndrome: a systematic review and meta-analysis

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 75, No 7 (2017)

Pages

666-673

Published online

2017-03-31

DOI

10.5603/KP.a2017.0068

Bibliographic record

Kardiol Pol 2017;75(7):666-673.

Keywords

platelet-to-lymphocyte ratio
acute coronary syndrome
all-cause mortality
major adverse cardiovascular events
meta-analysis

Authors

Hui Li
Yun Zhou
Yan Ma
Suxia Han
Liansuo Zhou

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl